Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07427797 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
A Phase 3 study of Moderate to Severe Glabellar Lines, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07427797 is a Phase 3 study of Moderate to Severe Glabellar Lines that is actively recruiting participants, run by Ipsen. The registered enrollment target is 300 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT07427797, a Phase 3 study of Moderate to Severe Glabellar Lines, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable with age or repeated facial expressions. They may affect a person's appearance and confidence. In this study, all participants will receive a single injection of either IPN10200 or placebo (the study drug). There will be 3 periods in this study: * A screening period (up to 20 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period (Day 1) where all the eligible participants will receive a single injection of IPN10200 or placebo. * A follow-up period (52 weeks) where participants' health will be monitored, consisting of regular visits to the study centre and 1 telephone call visit. Participants will undergo health measurements and observation, including blood sampling, physical examinations, clinical evaluations and electrocardiograms (ECG: recording of the electrical activity of heart). They will also be asked to fill in questionnaires and keep a diary. Each participant will be in this study for up to 55 weeks. Participants may withdraw consent to participate at any time.
Conditions Studied
Interventions
- BIOLOGICAL IPN10200
- BIOLOGICAL Placebo
Study Locations (20)
California
- Ablon Skin Institute and Research Center - Manhattan Beach
- Keith A. Marcus, MD Inc - Redondo Beach
- West Dermatology - San Diego
- Ava T. Shamban, M.D., Inc. - Santa Monica
- Art of Skin MD - Solana Beach
- Pacific Clinical Innovations Inc. - Vista
Arizona
- Advanced Research Associates - Glendale
- Avacare - Scottsdale
- Investigate MD, LLC - Scottsdale
Texas
- Westlake Dermatology & Cosmetic Surgery - Westlake - Austin
- Dermatology and Laser Surgery Center - Houston
- Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research - Pflugerville
British Columbia
- Carruthers and Humphrey Cosmetic Medicine - Vancouver
- Pacific Dermaesthetics Inc. - Vancouver
Alabama
- Skin Wellness Dermatology - Homewood - Birmingham
Florida
- Skin Research Institute - Coral Gables
Maryland
- ICON Dermatology and Aesthetics - Bethesda
South Carolina
- Clinical Research Center of the Carolinas - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-02-27 |
| Est. Completion | 2027-07-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07427797
The ClinicalTrials.gov registry entry for NCT07427797 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate to Severe Glabellar Lines appearing as the primary indexed condition, and to 2 interventions - of which IPN10200 is the first listed.
NCT07427797 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT07427797 about?
NCT07427797 is a clinical study titled "A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows". The purpose of this study is to assess the effectiveness and safety of IPN10200 compared to placebo in the improvement of the appearance of moderate to severe glabellar lines in adult participants. Glabellar lines are wrinkle-like lines that appear between the eyebrows and can become more noticeable...
What is the current status of trial NCT07427797?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-02-27. Estimated completion is 2027-07-15.
What conditions does trial NCT07427797 study?
This clinical trial studies the following conditions: Moderate to Severe Glabellar Lines.
What interventions are being tested in trial NCT07427797?
The interventions under investigation include: IPN10200 (BIOLOGICAL), Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT07427797?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07427797 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate to Severe Glabellar Lines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.